Abstract
Hantaviruses are associated with two human diseases: hemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS). These viruses are carried by persistently infected rodents, and are transmitted to humans by aerosolized rodent excreta. HFRS is characterized by fever, hemorrhagic manifestations, renal dysfunction, and shock. HPS is characterized by fever, headache, myalgia, and gastrointestinal symptoms, followed by noncardiogenic pulmonary edema, and shock. Although there are orders of magnitude fewer HPS cases than HFRS cases, the small outbreaks of HPS that have occurred have been highly lethal, with case-fatality rates of 40-60%. In addition, there is evidence that at least one of the HPS hantaviruses can be transmitted from person-to-person (Wells et al. 1997). Since 1993, 555 HPS cases have been reported in the United States, Canada, and several countries in South America. Recently, for the first time, a hantavirus was associated with an outbreak of lethal acute febrile respiratory illness in Central America (Bayard et al. 2000). A summary of hantaviruses that are known to cause human disease are shown in Table 1.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ahn CN (1997) Hemorrhagic fever with renal syndrome (HFRS) vaccine in Korea WHO working group on prevention and control of Hantavirus infections. (Abstract) Seoul 5–6 Nov 1997
Arikawa J, Yao JS, Yoshimatsu K, Takashima I, Hashimoto N (1992) Protective role of antigenic sites on the envelope protein of Hantaan virus defined by monoclonal antibodies. Arch Virol 126, 271–281
Bayard V, et al. (2000) Hantavirus pulmonary syndrome: Panama, 1999–2000. MMWR 49:205–207
Bharadwaj M, Lyons RC, Wortman IA, Hjelle B (1999) Intramuscular inoculation of Sin Nombre hantavirus cDNAs induces cellular and humoral immune responses in BALB/c mice. Vaccine 17:2836–2843
Chen HX, Luo ZZ, Zhang JJ (1999) Study on epidemiological efficacy and immunologic strategy of vaccines against hemorrhagic fever with renal syndrome Chinese Public Health 15:561–8 (in Chinese)
Cho HW, Howard CR (1999) Antibody responses in humans to an inactivated hantavirus vaccine (Hantavax) Vaccine 4:2569–75
Chu YK, Jennings GB, Schmaljohn CS (1995) A vaccinia virus-vectored Hantaan virus vaccine protects hamsters from challenge with Hantaan and Seoul viruses but not Puumala virus. J Virol 69:6417–6423
Dong GM, An Q, Zhu ZY (1998) Expanded human trail of the bivalent HFRS inactivated vaccine made from M. gerbil kidney tissue culture. Chin J Microbiol Immunol 18:453–456
Dubensky T, Driver D, Polo J, Belli B, Latham E, Ibanex C, Chada S, Brumm D, Banks T, Mento S, Jolly D, Chang S (1996) Sindbis virus DNA-based expression vectors: utility for in vitro and in vivo gene therapy. J Virol 70:508–519
Frolov I, Hoffman TA, Pragai BM, Dryga SA, Huang HV, Schlesginer S, Rice CM (1996) Alphavirus-based expression vectors: strategies and applications. Proc Natl Sci USA 93:11 371–11 377
Hao FY, Hui LG, Zhao XL, Wang XH, Han L, Huang YC (1996) Efficacy test for inactivated epidemic hemorrhage fever vaccine using golden hamsters. Chin J Biol 9:69–72 (in Chinese)
Hooper JW, Kamrud KI, Elgh F, Custer D, Schmaljohn CS (1999) DNA vaccination with hantavirus M segment elicits neutralizing antibodies and protects against Seoul virus infection. Virology 255: 269–278
Kamrud KI, Hooper JW, Elgh F, Schmaljohn CS (1999) Comparison of protective efficacy of naked DNA, DNA-based replicon, and packaged Sindbis replicon vectors expressing hantavirus structural genes in hamsters. Virology 263:209–219
Kim RJ, Ru C, Kim GM (1991) The special prevention of HFRS in P.D.R of Korea. Chinese Clin Exper Virol 4:487–92 (in Chinese)
Lee H, Ahn C, Song J, Baek L, Seo T, Park S (1990) Field trial of an inactivated vaccine against hemorrhagic fever with renal syndrome in humans. Arch Virol (Suppl 1):35–47
Liu PQ, Liao HX, Fu JL (1984) Isolation of epidemic hemorrhagic fever viruses from Rattus losea and R. Confucianus, and their antigenic identification. Bull Jiangxi Med Coll 3:1 (in Chinese)
Liu WM, Song G, Zhang QF (1992) Comparative studies on inactivating methods for production of inactivated cell culture vaccine against epidemic hemorrhagic fever. Chin J Virol 3:141–146 (in Chinese)
Lundkvist Å, Kallio-Kokko H, Brus-Sjölander K, Lankinen H, Niklasson B, Vaheri A, Vapalahti O (1996) Characterization of Puumala virus nucleocapsid protein: identification of B-cell epitopes and domains involved in protective immunity. Virology 216:397–406
McClain DJ, Summers PL, Harrison SA, Schmaljohn AL, Schmaljohn CS (2000) Clinical evaluation of a vaccinia-vectored Hantaan virus vaccine. J Med Virol 60:77–85
Oya A (1976) Japanese encephalitis vaccine: the vaccination. Int Medical Found Japan 1976:69–72
Pensiero MN, Jennings GB, Schmaljohn CS, Hay J (1988) Expression of the Hantaan virus M genome segment by using a vaccinia virus recombinant. J Virol 62:696–702
Ren K, Lu QX, Song G, Huang YC, Sun RH, Wang S (1996) Serological efficacy of the inactivated golden hamster kidney cell vaccine against hemorrhagic fever with renal syndrome in human trial. Chin J Exp Clin Virol 10:10–15 (in Chinese)
Robinson HL, Torres CA (1997) DNA vaccines. Semin Immunol 9:271–283
Schmaljohn CS (1996) Molecular Biology of Hantaviruses. In: Elliott RM (ed) The Bunyaviridae. New York, Plenum Press pp 63–90
Schmaljohn CS, Chu YK, Schmaljohn AL, Dalrymple JM (1990) Antigenic subunits of Hantaan virus expressed by baculovirus and vaccinia virus recombinants. J Virol 64:3162–3170
Schmaljohn CS, Hasty SE, Dalrymple JM (1992) Preparation of candidate vaccinia-vectored vaccines for haemorrhagic fever with renal syndrome. Vaccine 10:10–13
Smadel JE (1953) Epidemic hemorrhagic fever. Am J Pub Hlth 43:13327–13335
Ulrich R, Lundkvist Å, Meisel H, Koletzki D, Brus Sjölander K, Gelderblom HR, Borisova G, Schnitzler P, Darai G, Kruger DH (1998) Chimaeric HBV core particles carrying a defined segment of Puumala hantavirus nucleocapsid protein evoke protective immunity in an animal model. Vaccine 16:272–280
Ulrich R, Koletzki H, Lachmann S, Lundkvist Å, Zankl A, Kazaks A, Kurth A, Gelderblom R, Borisova G, Meisel H, Kruger DH (1999) New chimaeric hepatitis B virus core particles carrying hantavirus (serotype Puumala) epitopes: immunogenicity and protection against virus challenge. J Biotechnol 73:141–153
Wells RM, Sosa Estani S, Yadon ZE, Enria D, Padula P, Pini N, Mills JN, Peters CJ, Segura EL (1997) An unusual hantavirus outbreak in southern Argentina: person-to-person transmission? Hantavirus Pulmonary Syndrome Study Group for Patagonia. Emerg Infect Dis Apr-Jun3:171–174
Xu X, Ruo SL, McCormick JB, Fisher-Hoch SP (1992) Immunity to Hantavirus challenge in Meriones unguiculatus induced by vaccinia-vectored viral proteins. Am J Trop Med Hyg 47:397–404
Yamanishi K, Tanishita O, Tamura M, Asada H, Kondo K, Takagi M, Yoshida I, Konobe T, Fukai K (1988) Development of inactivated vaccine against virus causing haemorrhagic fever with renal syndrome. Vaccine 3:278–282
Yoshimatsu K, Yoo YC, Yoshida R, Ishihara C, Azuma I, Arikawa J (1993) Protective immunity of Hantaan virus nucleocapsid and envelope protein studied using baculovirus expressed proteins. Arch Virol 130:365–376
Yu YX, Yao XJ, Dong GM, An Q, Li ZP (1990) Antibody response of inactivated HFRS vaccine to homologous and heterologous types of the virus. Chin J Biol 3:14–16
Yu YX, Liu WX, Nei ZL (1992) Neutralizing antibody response in humans immunized with Meriones gerbil kidney tissue culture inactivated HFRS vaccine assesed by two methods. Virol Sin 7:176–180
Zhu ZY, Zeng RF, Yu XY (1991) Efficacy of inactivated EHF vaccine in clinical trial. Virol Sin 6: 315–319
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Hooper, J.W., Li, D. (2001). Vaccines Against Hantaviruses. In: Schmaljohn, C.S., Nichol, S.T. (eds) Hantaviruses. Current Topics in Microbiology and Immunology, vol 256. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56753-7_10
Download citation
DOI: https://doi.org/10.1007/978-3-642-56753-7_10
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62491-9
Online ISBN: 978-3-642-56753-7
eBook Packages: Springer Book Archive